Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.

Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.

• Publication year

  2018

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2018-01-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.biopha.2018.02.108PMID 29501768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lapatinib

  2020cited by this paper
• Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

  2018cited by this paper
• Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

  2018cited by this paper
• Metabolism of megestrol acetate in vitro and the role of oxidative metabolites

  2018cited by this paper
• Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.

  2018cited by this paper
• Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

  2018cited by this paper
• Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

  2018cited by this paper
• Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

  2018cited by this paper
• Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

  2018cited by this paper
• Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer

  2018cited by this paper
• Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.

  2018cited by this paper
• Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

  2018cited by this paper
• Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

  2017cited by this paper
• Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

  2017cited by this paper
• Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

  2017cited by this paper
• Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer

  2017cited by this paper
• Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

  2017cited by this paper
• A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

  2017cited by this paper
• Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First‐Line Treatment of Metastatic Triple‐Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

  2017cited by this paper
• Combined Raloxifene and Letrozole for Breast Cancer Patients.

  2017cited by this paper
• Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

  2017cited by this paper
• New agents for the management of resistant metastatic breast cancer

  2017cited by this paper
• Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial

  2017cited by this paper
• Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer

  2017cited by this paper
• Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

  2017cited by this paper
• Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors

  2017cited by this paper
• Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle

  2017cited by this paper
• Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

  2017cited by this paper
• Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

  2017cited by this paper
• A prospective study of docetaxel-associated pain syndrome

  2017cited by this paper
• Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

  2017cited by this paper
• Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.

  2017cited by this paper
• A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer.

  2017cited by this paper
• Advances in targeting HER2-positive breast cancer

  2017cited by this paper
• Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.

  2017cited by this paper
• A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

  2017cited by this paper
• Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review

  2017cited by this paper
• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

  2017cited by this paper
• Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

  2017cited by this paper
• Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015

  2017cited by this paper
• Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study

  2017cited by this paper
• Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil: a prospective cohort study

  2017cited by this paper
• Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience

  2017cited by this paper
• The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials

  2017cited by this paper
• First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

  2017cited by this paper
• Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.

  2017cited by this paper
• Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes

  2017cited by this paper
• Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

  2017cited by this paper
• Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer

  2017cited by this paper
• PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

  2017cited by this paper
• Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

  2017cited by this paper
• Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value

  2017cited by this paper
• Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2‐neu Negative and Triple Negative Metastatic Breast Cancer

  2017cited by this paper
• Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study

  2017cited by this paper
• Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.

  2017cited by this paper
• TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.

  2017cited by this paper
• Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer

  2017cited by this paper
• Enrichment of high-grade tumors in breast cancer gene expression studies

  2017cited by this paper
• First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.

  2017cited by this paper
• Joint symptoms associated with anastrozole and letrozole in patients with breast cancer: a retrospective comparative study

  2017cited by this paper
• Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

  2017cited by this paper
• Antineoplastic effects of clove buds (Syzygium aromaticum L.) in the model of breast carcinoma

  2017cited by this paper
• A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

  2016cited by this paper
• Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study

  2016cited by this paper
• Do platinum salts fit all triple negative breast cancers?

  2016cited by this paper
• Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

  2016cited by this paper
• Platinum-based drugs: past, present and future

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.

  2016cited by this paper
• Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases

  2016cited by this paper
• Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine

  2016cited by this paper
• 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

  2016cited by this paper
• A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

  2016cited by this paper
• Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.

  2016cited by this paper
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

  2016cited by this paper
• Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

  2016cited by this paper
• Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

  2016cited by this paper
• Anticancer activity of a cis-dichloridoplatinum(ii) complex of a chelating nitrogen mustard: insight into unusual guanine binding mode and low deactivation by glutathione.

  2016cited by this paper
• Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

  2016cited by this paper
• A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.

  2016cited by this paper
• SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

  2016cited by this paper
• Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

  2016cited by this paper
• Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.

  2016cited by this paper
• Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients

  2016cited by this paper
• Treating cancer with selective CDK4/6 inhibitors

  2016cited by this paper
• Aromatase inhibitors in premenopause: Great expectations fulfilled?

  2016cited by this paper
• Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

  2016cited by this paper
• Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

  2016cited by this paper
• Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

  2016cited by this paper
• Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).

  2016cited by this paper
• Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

  2016cited by this paper
• Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer

  2015cited by this paper
• Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)

  2015cited by this paper
• Gene expression profiling of histologically normal breast tissue in females with human epidermal growth factor receptor 2‑positive breast cancer.

  2015cited by this paper
• Mechanisms of aromatase inhibitor resistance

  2015cited by this paper
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

  2015cited by this paper
• Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

  2015cited by this paper
• Bisphosphonates in breast cancer

  2015cited by this paper
• Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.

  2015cited by this paper

• Ameliorative effect of pomegranate peel extract nanoparticles and ovarian stem cells-derived exosomes on cyclophosphamide-induced premature ovarian insufficiency

  2026cites this paper
• Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review

  2025cites this paper
• Synthesis and Screening of 1-Methylisatin-linked 1,2,3-Triazoles as VEGFR-2 Inhibitors and Their Molecular Docking Studies

  2025cites this paper
• Polymeric Nanoparticles with Surface-Anchored Functional Groups as Chelating Agents for Calcium (Ca2+) and Magnesium (Mg2+) Ions to Inhibit Cellular Interactions

  2025cites this paper
• Co-Encapsulation of Doxorubicin HCl and Paclitaxel in Nanovesicles for Enhanced Breast Cancer Therapy

  2025cites this paper
• Evaluation of antileukemic potentials of maslinic acid through targeting responsive proteins of human leukemia: a mechanistic perception on molecular modelling and dynamic stimulations

  2025cites this paper
• Chemotherapy-Induced Cardiotoxicity in Breast Cancer: Mechanisms, Diagnostic Advances, and Emerging Protective Strategies.

  2025cites this paper
• Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies

  2025cites this paper
• Novel Sulfonamide Derivatives as Anticancer Agents, VEGFR‑2 Inhibitors, and Apoptosis Triggers: Design, Synthesis, and Computational Studies

  2025cites this paper
• Dichloroacetate enhances Chemo-sensitivity in wild-type P53 breast cancer cells by modulating ABCG2 and NKG2DL

  2025cites this paper
• Strontium decorated mebendazole alginate nano-platform for bone marrow active targeting for the treatment of bone metastasis

  2025cites this paper
• Detection of Cytotoxic Antimetabolites in Water: Current Analytical Methods.

  2025cites this paper
• Study the impact of Galangin and Alpinia galanga L. on the activation of apoptosis in breast cancer

  2025cites this paper
• The impact of serum interleukin-17a as a predictive biomarker for neoadjuvant therapy response in breast cancer: a retrospective study

  2025cites this paper
• Beyond Conventional Approaches: The Revolutionary Role of Nanoparticles in Breast Cancer

  2025cites this paper
• Synthesis and Evaluation of Novel Dimethyltriazene Epoxide and 2-Thioxotetrahydropyrimidin-5(2H)-one Derivatives as Potential Anticancer Agents

  2025cites this paper
• Common Drug-Drug and Drug-Food Interactions in Antineoplastic Agents: A short update review

  2025cites this paper
• Folate Receptor-Targeted Camptothecin-Loaded PLGA-Glutenin Nanoparticles for Effective Breast cancer Treatment

  2024cites this paper
• The Quality of Life Breast Cancer Patients Receiving Chemotherapy and The Factors Affecting It in a Regional Hospital in Gianyar

  2024cites this paper
• The interaction of cinchonine and immunoglobulin G and the development of a nanocomplex with improved anti-breast cancer activity.

  2024cites this paper
• Breast Cancer Treatment: The Potential of Organic and Inorganic Nanocarriers in Targeted Drug Delivery

  2024cites this paper
• Macromolecular Poly(N‐isopropylacrylamide) (PNIPAM) in Cancer Treatment and Beyond

  2024cites this paper
• The Potential of Plant Polysaccharides and Chemotherapeutic Drug Combinations in the Suppression of Breast Cancer

  2024cites this paper
• Organocatalytic[3 + 2]Cycloaddition: Synthesis of Quinazoline Containing Sulfonyl 1,2,3‐Triazoles as Potent EGFR Targeting Anti‐Breast Cancer Agents

  2024cites this paper
• Anticancer potential of active alkaloids and synthetic analogs derived from marine invertebrates.

  2024cites this paper
• New uses of halofuginone to treat cancer

  2024cites this paper
• Development of cationic pH-sensitive liposomes with Gemcitabine loading and Fucoidan-coating against pancreatic cancer cells

  2024cites this paper
• Single-Cell Fluidic Force Spectroscopy Reveals Dynamic Mechanical Fingerprints of Malignancy in Breast Cancer

  2024cites this paper
• Fabrication of folic acid-conjugated pyrimidine-2(5H)-thione-encapsulated curdlan gum-PEGamine nanoparticles for folate receptor targeting breast cancer cells.

  2024cites this paper
• Theranostics Using MCM-41-Based Mesoporous Silica Nanoparticles: Integrating Magnetic Resonance Imaging and Novel Chemotherapy for Breast Cancer Treatment

  2024cites this paper
• An insight into the therapeutic effects of isoliquiritigenin in breast cancer

  2024cites this paper
• Dietary interventions and tumor response to chemotherapy in breast cancer: A comprehensive review of preclinical and clinical data.

  2024cites this paper
• Diterpenoids from the Aerial Parts of Isodon serra with Selective Cytotoxic Activity

  2024cites this paper
• Ag(I)-NHC/TBHP promoted aqueous synthesis of some new quinoline-aromatic amides; Anti-proliferative, Anti-VEGFR-2 and Molecular docking studies

  2024cites this paper
• Tuning of the Anti-Breast Cancer Activity of Betulinic Acid via Its Conversion to Ionic Liquids

  2024cites this paper
• An integrated approach to understand the regulatory role of miR-27 family in breast cancer metastasis

  2024cites this paper
• Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2‐Positive Breast Cancer

  2024cites this paper
• Assessing the ability of Polysaccharides extracted from Date Palm Fruit to salvage Wistar rats from cisplatin-linked hepatic damage

  2024cites this paper
• Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dual-drugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis.

  2024cites this paper
• Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications.

  2024cites this paper
• Engineered triphenylphosphonium-based, mitochondrial-targeted liposomal drug delivery system facilitates cancer cell killing actions of chemotherapeutics

  2023cites this paper
• Radiolabeled chemotherapeutics as a novel strategy for targeted cancer therapy: current insights and future perspectives

  2023cites this paper
• Bibliometric analysis and visualization of endocrine therapy for breast cancer research in the last two decade

  2023cites this paper
• Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer.

  2023cites this paper
• Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.

  2023cites this paper
• Targeted delivery of epirubicin to cancerous cell using copper sulphide nanoparticle coated with polyarginine and 5TR1 aptamer

  2023cites this paper
• Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin—A Review

  2023cites this paper
• Curcumin-Loaded Chitosan-Coated 5-Fluorouracil Encapsulated Nanozeolitic Imidazolate Framework for Combination Cancer Therapy

  2023cites this paper
• Recent Advances of Halloysite Nanotubes in Biomedical Applications.

  2023cites this paper
• MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel

  2023cites this paper
• Enhanced anticancer effect of Artemisia turcomanica extract in niosomal formation on breast cancer cells: In-vitro study

  2023cites this paper
• Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models

  2023cites this paper
• New SDS-Based Polyelectrolyte Multicore Nanocarriers for Paclitaxel Delivery—Synthesis, Characterization, and Activity against Breast Cancer Cells

  2023cites this paper
• Untangling breast cancer: Trailing towards nanoformulations-based drug development.

  2023cites this paper
• Adverse effects in the management of breast cancer – recent studies

  2023cites this paper
• A review of synthetic strategy, SAR, docking, simulation studies, and mechanism of action of isoxazole derivatives as anticancer agents

  2023cites this paper
• Synergy and Coordination Between Biomimetic Nanoparticles and Biological Cells/Tissues/Organs/Systems: Applications in Nanomedicine and Prospect

  2023influential citation
• A Comprehensive Pan-Cancer Analysis Identifies CEP55 as a Potential Oncogene and Novel Therapeutic Target

  2023cites this paper
• In Vitro and In Vivo Effects of Ulvan Polysaccharides from Ulva rigida

  2023cites this paper
• Assessment of Cytotoxic/Antitumour Potential and in Silico Study of Salazinic Acid Isolated from Parmotrema concurrens.

  2023cites this paper
• Identification of Flavone Derivative Displaying a 4′-Aminophenoxy Moiety as Potential Selective Anticancer Agent in NSCLC Tumor Cells

  2023cites this paper
• The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target

  2023cites this paper
• Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients.

  2023cites this paper
• Estradiol Levels and Chemotherapy in Breast Cancer Patients: A Prospective Clinical Study

  2023cites this paper
• Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

  2023cites this paper
• Organotropism of breast cancer metastasis: A comprehensive approach to the shared gene network

  2023cites this paper
• A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer

  2022cites this paper
• A novel, dual action chimera comprising DNA methylating agent and near-IR xanthene-cyanine photosensitizer for combined anticancer therapy.

  2022cites this paper
• Immunomodulatory properties of nanostructured systems for cancer therapy.

  2022cites this paper
• New strategies in microbial screening for novel chemotherapeutics

  2022cites this paper
• Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer

  2022cites this paper
• Programmed Cell Death Alterations Mediated by Synthetic Indole Chalcone Resulted in Cell Cycle Arrest, DNA Damage, Apoptosis and Signaling Pathway Modulations in Breast Cancer Model

  2022cites this paper
• Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation

  2022cites this paper
• The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer

  2022cites this paper
• Quinoline conjugated 2-azetidinone derivatives as prospective anti-breast cancer agents: In vitro antiproliferative and anti-EGFR activities, molecular docking and in-silico drug likeliness studies

  2022cites this paper
• A novel anticancer property of Lycium barbarum polysaccharide in triggering ferroptosis of breast cancer cells

  2022cites this paper
• An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy.

  2022cites this paper
• Combining Imaging and Drug Delivery for Cancer Treatment.

  2022cites this paper
• Regulation of mitochondrial fusion and mitophagy by intra-tumoral delivery of membrane-fused mitochondria or Midiv-1 enhances sensitivity to doxorubicin in triple-negative breast cancer.

  2022cites this paper
• In Vitro and In Silico Study to Assess Toxic Mechanisms of Hybrid Molecules of Quinone-Benzocaine as Plastoquinone Analogues in Breast Cancer Cells

  2022cites this paper
• Prime Editing: An Emerging Tool in Cancer Treatment

  2022cites this paper
• Nano-Clays for Cancer Therapy: State-of-the Art and Future Perspectives

  2022cites this paper
• Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer.

  2022cites this paper
• Analysis of Cell Proliferation and Apoptosis in Virtual Model

  2022cites this paper
• Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer

  2022cites this paper
• Cytotoxicity of curcumin-loaded magnetic nanoparticles against normal and cancer cells as a breast cancer drug delivery system

  2022cites this paper
• Cytotoxicity towards Breast Cancer Cells of Pluronic F-127/Hyaluronic Acid Hydrogel Containing Nitric Oxide Donor and Silica Nanoparticles Loaded with Cisplatin

  2022cites this paper
• Studies on 1,4-Quinone Derivatives Exhibiting Anti-Leukemic Activity along with Anti-Colorectal and Anti-Breast Cancer Effects

  2022cites this paper
• Knowledge, Attitude, and Practice of Oncologists toward Chemotherapy Resistance: A Questionnaire Development and Pilot Testing

  2022cites this paper
• Natural isoflavonoids in invasive cancer therapy: From bench to bedside

  2021cites this paper
• The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1).

  2021cites this paper
• The Role of ATRA, Natural Ligand of Retinoic Acid Receptors, on EMT-Related Proteins in Breast Cancer: Minireview

  2021cites this paper
• Recent advances in targeted nanotherapeutic approaches for breast cancer management.

  2021cites this paper
• The Future Perspectives of Drug Repurposing and Treatment for the Drug Resistant Breast Cancer: A Review

  2021cites this paper
• P2X7 receptor: a critical regulator and potential target for breast cancer

  2021cites this paper
• Cancer-Targeted Nanotheranostics: Recent Advances and Future Perspectives

  2021cites this paper
• A Network Pharmacology Analysis of the Systems-Perspective Anticancer Mechanisms of the Herbal Drug FDY2004 for Breast Cancer

  2021cites this paper
• The anti-cancer potential of 2,4,6 tris-methyphenylamino1,3,5-triazine compound against mammary glands cancer: Via down-regulating the hormonal, inflammatory mediators, and oxidative stress.

  2021cites this paper
• Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer

  2021cites this paper
• Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity

  2021cites this paper